1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,000 | 8,150 | 17:43 | |
| 8,000 | 8,150 | 17:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals | 121 | GlobeNewswire (Europe) | NANJING, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its Phase II clinical study evaluating... ► Artikel lesen | |
| 06.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR HEPATOCELLULAR CARCINOMA ... | 1 | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 04.08. | LEADS BIOLABS CO., LTD.: Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL-051 for Refractory Autoimmune Diseases | 201 | GlobeNewswire (Europe) | NANJING, China, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its partner company with Aditum Bio,... ► Artikel lesen | |
| 04.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PARTNER OBLENIO DOSES FIRST PATIENTS IN PHASE IA TRIAL OF LBL-051 FOR REFRACTORY AUTOIMMUNE DISEASES AND ... | - | HKEx | ||
| 03.08. | LEADS BIOLABS CO., LTD.: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise | 173 | GlobeNewswire (Europe) | NANJING, China, Aug. 02, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Center for Drug Evaluation (CDE)... ► Artikel lesen | |
| 03.08. | LEADS BIOLABS-B VLSIN New Drug Clinical Trial Application Approved to Expand Into Metastatic Colorectal Cancer Indication | 1 | AASTOCKS | ||
| 03.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) RECEIVED IND APPROVAL FROM NMPA FOR THE TREATMENT ... | 1 | HKEx | ||
| 30.07. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Completes Patient Enrollment in Phase II Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors | 664 | GlobeNewswire (Europe) | NANJING, China, July 30, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the Phase II clinical study of its core product... ► Artikel lesen | |
| 30.07. | LEADS BIOLABS-B Completes Enrollment for All Patients in Phase II Clinical Study of WeliXin for First-line Treatment of Advanced Biliary Tract Cancer | 2 | AASTOCKS | ||
| 30.07. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - COMPLETION OF FULL PATIENT ENROLLMENT IN PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ... | 3 | HKEx | ||
| 24.07. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY THE CHIEF EXECUTIVE OFFICER | - | HKEx | ||
| 13.07. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT MULTIPLE RESEARCH RESULTS SELECTED FOR PRESENTATION AT 2026 ESMO | - | HKEx | ||
| 10.07. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) INCLUDED IN THE PRIORITY REVIEW AND APPROVAL ... | 1 | HKEx | ||
| 01.07. | LEADS BIOLABS-B (09887): GRANT OF AWARDS PURSUANT TO THE H SHARE AWARD SCHEME | 1 | HKEx | ||
| 25.06. | LEADS BIOLABS CO., LTD.: Leads Biolabs Announces Partner Oblenio Bio's $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development | 5 | GlobeNewswire (USA) | ||
| 25.06. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PARTNER OBLENIO CLOSES OVERSUBSCRIBED US$62 MILLION SERIES B FINANCING ROUND TO ACCELERATE CLINICAL DEVELOPMENT ... | - | HKEx | ||
| 05.06. | LEADS BIOLABS-B (09887): INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION | - | HKEx | ||
| 05.06. | LEADS BIOLABS-B (09887): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 28.05. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - ORAL PRESENTATION OF PHASE II CLINICAL STUDY RESULTS OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ... | 1 | HKEx | ||
| 20.05. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET ACQUISITION OF H SHARES BY THE TRUSTEE IN THE AMOUNT OF UP TO US$50 MILLION UNDER THE ... | - | HKEx |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS | 32,550 | +51,89 % | Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday | ||
| APOGEE THERAPEUTICS | 134,59 | 0,00 % | This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday | ||
| QIAGEN | 36,910 | -0,43 % | DAX Gewinner am Montag: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| PRAXIS PRECISION MEDICINES | 370,34 | -1,48 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| TARSUS PHARMACEUTICALS | 70,40 | -0,30 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position | Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,775 | -0,04 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| EVOTEC | 3,344 | -2,56 % | Evotec Aktie: Lebenszeichen aus der Totenstille - wer kauft denn da? | Die auffällige Ruhe bei der Evotec Aktie, die im letzten 4investors.de-Chartcheck im Mittelpunkt stand, ist durchbrochen. Damals lautete die Frage, ob jemand leise in die Totenstille der Biotechnologie-Aktie... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,180 | -0,38 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,160 | -3,34 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| VERA THERAPEUTICS | 31,690 | +0,19 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| KYMERA THERAPEUTICS | 119,22 | -1,80 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 2,935 | -5,63 % | Recursion auf der Bank of America SMID Cap Virtual Conference: Wetten auf KI | ||
| 4D MOLECULAR THERAPEUTICS | 14,290 | -1,75 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | ||
| ENLIVEN THERAPEUTICS | 59,89 | +0,60 % | Barclays startet Coverage für Enliven Therapeutics mit "Overweight" und Kursziel von 78 Dollar | ||
| EDGEWISE THERAPEUTICS | 44,140 | +0,23 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen |
NANJING LEADS BIOLABS CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,64 % bei einem Aktienkurs von 7,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.